1258 studies found for:    Doxorubicin (liposomal) OR Doxil[TREATMENT] AND HIV [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
Doxorubicin (liposomal) OR Doxil[TREATMENT] AND HIV [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate;   Drug: Doxorubicin hydrochloride
2 Completed Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Filgrastim;   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate
3 Completed Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
Conditions: Sarcoma, Kaposi;   HIV Infections
Intervention: Drug: Doxorubicin hydrochloride (liposomal)
4 Completed Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate
5 Completed Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
Condition: AIDS-related Kaposi Sarcoma
Interventions: Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
6 Completed A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Intervention: Drug: Doxorubicin hydrochloride (liposomal)
7 Completed A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Daunorubicin (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate;   Drug: Doxorubicin hydrochloride
8 Recruiting Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
9 Active, not recruiting AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Conditions: Cancer;   Carcinoma;   Fallopian Tube Cancer;   Gynecological Malignancies;   Metastases;   Oncology;   Ovarian Cancer;   Solid Tumors;   Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin;   Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin;   Drug: B1: AMG 386 10 mg/kg + Topotecan;   Drug: B3: AMG 386 15mg/kg + Topotecan
10 Terminated MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
Condition: Ovarian Cancer
Intervention: Drug: MK-4827 + pegylated liposomal doxorubicin
11 Completed Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Carcinoma
Interventions: Drug: Pazopanib;   Drug: Doxil
12 Suspended Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
Conditions: Solid Tumors;   Lymphomas
Interventions: Drug: Recombinant human TNF-α;   Drug: Liposomal doxorubicin;   Drug: Caelyx
13 Completed A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3;   Drug: liposomal doxorubicin
14 Terminated Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Telcyta;   Drug: Liposomal Doxorubicin
15 Completed Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: sargramostim;   Drug: methotrexate;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: vincristine sulfate
16 Withdrawn Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin;   Drug: Seliciclib
17 Completed Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Condition: Sarcoma
Intervention: Drug: temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
18 Unknown  Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Drug: Liposomal doxorubicin;   Drug: Cisplatin
19 Completed Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
Condition: Resistant Solid Malignancies
Interventions: Drug: Temsirolimus;   Drug: Pegylated liposomal doxorubicin
20 Completed Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
Condition: Advanced Cancer
Interventions: Drug: Cisplatin;   Drug: Liposomal Doxorubicin

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years